Jeet Gandhi (1), Kiran Godse (2), Gauri Godse (3),
(1) Consultant Dermatologist, Sakhiya Skin Clinic, Surat, Gujarat, India
(2) Professor of Dermatology, D Y Patil Hospital, Navi Mumbai, Maharashtra, India
(3) Shree Skin Centre, Navi Mumbai, Maharashtra, India
(1) Consultant Dermatologist, Sakhiya Skin Clinic, Surat, Gujarat, India
(2) Professor of Dermatology, D Y Patil Hospital, Navi Mumbai, Maharashtra, India
(3) Shree Skin Centre, Navi Mumbai, Maharashtra, India
Bilastine is a new second generation H1‐antihistamine approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU) in patients older than 12 years of age. AR and urticaria are very common clinical conditions that represent one of the most frequent reasons for a patient to visit their general practitioner or allergist or dermatologist. Bilastine, with its efficacy and safety profile epitomizes the evolution of research on antihistamines.
